Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy

Table 3 Risk factors for OS by univariate and multiple Cox proportional hazards regression analysis

	Univariate Multivariate
Parameters	HR(95%CI)	p value	HR(95%CI)	p value
Age (high vs low)	1.13(0.57–2.17)	0.587
Gender (male vs female)	1.49(0.76–2.78)	0.224
Current smokers (yes vs no)	1.11(0.60–1.97)	0.754
Alcohol (yes vs no)	1.42(0.75–2.55)	0.215
Diabetes (yes vs no)	1.78(0.61–4.45)	0.287
Hypertension (yes vs no)	1.14(0.53–2.51)	0.678
ECOG PS (0 vs ≥1)	0.88(0.45–1.61)	0.612
Tumor size (T1/T2 vs T3/T4)	1.67(0.92–3.15)	0.089	1.88(0.92–3.58)	0.073
Lymph node (N0 vs N1–3)	1.92(0.87–3.98)	0.142
Metastasis stage (M0 vs M1a/b)	2.06(1.07–3.88)	0.024*	1.73(0.90–2.92)	0.093
Differentiation (Well/moderate vs poor)	1.55(1.04–2.36)	0.041*	1.22(0.81–1.72)	0.312
Histology (AC vs non-AC)	1.24(0.70–2.14)	0.412
Chemotherapy (DP vs AP/GP)	1.43(0.88–2.45)	0.126
CRP (high vs low)	1.39(0.78–2.43)	0.244
AFR (≤8.02 vs > 8.02)	1.93(1.28–2.98)	0.011*	1.79(1.11–2.59)	0.029*

NSCLC Non–small cell lung cancer, ECOG PS Eastern cooperative oncology group performance status, TNM Tumor–node–metastasis, SCC Squamous carcinoma, AC Adenocarcinoma, DP Docetaxel combined with platinum, AP Pemetrexed combined with platinum, GP Gemcitabine combined with platinum, CRP C-reactive protein, AFR Albumin-to-fibrinogen ratio, OS Overall survival, HR Hazard ratio, CI Confidence interval. *P < 0.05

ISSN: 1471-2407